Skip to main content
$254.36 -3.71 (-1.44%) At close · Jul 29
Market Cap
$1.97B
Shares
7.74M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$258.07 Open$251.28 Day$249.91–259.00 52W$173.86–279.49 Avg vol 30d213K Short int1.2M · 16.1% float · 5.1d Short vol74% Last earningsMay 4, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 8

Up next

Next earnings call
Aug 2, 2026 Est · unconfirmed · this week
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 8, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 20.7 · elevated Equity put/call 0.61
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +15%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 59
      neutral
      MACD trend Negative
      52-week position 80%
      mid-range
      Momentum
      relative strength
      Neutral
      1-month return −2%
      trailing
      6-month return +3%
      trailing
      YTD return +16%
      this year
      Relative strength −5%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $238 › 200d $224 — 50d above 200d
      Institutional flow Accumulating
      81 of 272 funds reported for Jun 30 · net +69.9K sh shares · +13 new
      Insider flow Distributing
      Net -$922.1K over 90 days · 100% sells
      Short interest Falling
      16.07% of float · ▼ -6.9% MoM · 5.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      272 holders — mid 3-yr range
      Squeeze score 67
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +20%
      Y/Y
      Gross margin 28%
      contracting
      EPS growth +15%
      Y/Y
      Free cash flow $82.2M
      Valuation P/E 29
      below peers
      Buyback $10.0M
      authorized
      Balance sheet $115.2M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 46%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 4.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2025
      Revenue impact · Q3 $7M
      Operating income impact · Q3 $2.5M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +15% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      59 Neutral
      MACD trend
      Negative Bearish
      52-week position
      80% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $238 › 200d $224 — 50d above 200d
      Institutional flow Accumulating
      81 of 272 funds reported for Jun 30 · net +69.9K sh shares · +13 new
      Insider flow Distributing
      Net -$922.1K over 90 days · 100% sells
      Short interest Falling
      16.07% of float · ▼ -6.9% MoM · 5.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      272 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $174 Now $258 · 80% 52-wk high $279
      vs 200-day avg +15% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Adjusted net income non-GAAP $19.3M first quarter of 2026
      Adjusted EBITDA non-GAAP $121.1M year ended December 31, 2025
      Organic sales growth rate non-GAAP 1.5% year ended December 31, 2025

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      UFPT
      Ufp Technologies Inc
      this stock
      $1.97B +16.2% +19.5% 29.0 16.1%
      ABT
      Abbott Laboratories
      $186.84B -13.9% +5.7% 30.1 1.4%
      SYK
      Stryker Corp
      $132.87B -1.1% +11.2% 40.1 1.8%
      MDT
      Medtronic plc
      $111.21B -8.8% +8.4% 23.3 1.5%
      BSX
      Boston Scientific Corp
      $68.43B -51.7% +5.5% 19.3 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      277
      % held
      112.5%
      Reported
      81 of 272
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      285
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.2M
      Days to cover
      5.1d
      Change
      -92.0K sh
      View
      Short Volume
      Short vol %
      74%
      As of
      Jul 29, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.7K
      Value
      $968.8K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      44.2%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$922.1K
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $602.8M
      Net income (FY)
      $68.3M
      EPS diluted
      $8.75
      View
      Buybacks
      Authorized
      $10.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 10, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $635.0K
      Shares
      2.9K
      Filed
      May 12, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      UFPT +5.8% -2.1% +2.6% -2.7% +16.2%
      SPY -1.0% 0.0% +7.4% -0.8% +8.6%
      vs SPY +6.8% -2.1% -4.8% -1.9% +7.6%

      Capital returns

      Buyback program · as of Jun 16, 2015
      Authorized
      $10.00M
      Spent (derived)
      Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 914156 CUSIP 902673102 13F (30d) 78 filings 74 filers Visit website